A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis

Mansoor Rastegarpanah; Reza Malekzadeh; Homayoun Vahedi; Maryam Mohammadi; Elham Elahi; Meghedi Chaharmahali; Tahereh Safarnavadeh; Mohammad Abdollahi

doi:10.1007/s11655-012-1026-x

Your Location：

Home >

Browse articles >

A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis

Updated：2021-08-27

- A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis
- Chinese Journal of Integrative Medicine Vol. 21, Issue 12, Pages: 902-906(2015)
- Affiliations：
  
  1. Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran,Iran
  2. Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran,Iran
  3. Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran,Iran
  4. Pharmaceutical Branch, Islamic Azad University, Tehran,Iran
- Author bio：
- Funds：
- DOI：10.1007/s11655-012-1026-x
  CLC：
- Published：2015，
  
  Published Online：11 April 2012，
Scan for full text
Rastegarpanah, M., Malekzadeh, R., Vahedi, H. et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis., Chin. J. Integr. Med. 21, 902–906 (2015). https://doi.org/10.1007/s11655-012-1026-x

Mansoor Rastegarpanah, Reza Malekzadeh, Homayoun Vahedi, et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. [J]. Chinese Journal of Integrative Medicine 21(12):902-906(2015)
Rastegarpanah, M., Malekzadeh, R., Vahedi, H. et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis., Chin. J. Integr. Med. 21, 902–906 (2015). https://doi.org/10.1007/s11655-012-1026-x DOI：

Mansoor Rastegarpanah, Reza Malekzadeh, Homayoun Vahedi, et al. A randomized, double blinded, placebo-controlled clinical trial of silymarin in ulcerative colitis. [J]. Chinese Journal of Integrative Medicine 21(12):902-906(2015) DOI： 10.1007/s11655-012-1026-x.

摘要

To evaluate the clinical efficacy of silymarin in ulcerative colitis (UC) patients. A randomized double blinded placebo-controlled clinical trial was conducted in 80 UC patients whose disease had been documented and were in remission state between September 2009 and October 2010. Patients were assigned to silymarin group (42 cases) and placebo group (38 cases) using a random number table. Either silymarin (140 mg) or placebo (lactose mono-hydrate

corn starch magnesium stearate) tablets were given once daily for 6 months along with their standard therapy. The efficacies were assessed by disease activity index (DAI)

frequency difference of the disease flare-up

and paraclinical data. Ten patients (4 in the silymarin group due to nausea and 6 in the placebo group due to disease flare-up and abdominal pain) discontinued the study. An improvement in hemoglobin level (11.8±1.6 g/dL vs. 13.4±1.2 g/dL

P<0.05) and erythrocyte sedimentation rate (23.7±11.5 mm/h vs.10.8±3.2 mm/h

P<0.05) was observed in the silymarin group but not in the placebo group. DAI significantly decreased in the silymarin group and reached from 11.3±3.5 to 10.7±2.8 (P<0.05). Thirty-five out of 38 patients in the silymarin group were in complete remission with no flare-up after 6 months as compared to 21 out of 32 patients in the placebo group (P=0.5000). Silymarin as a natural supplement may be used in UC patients to maintain remission

Abstract

corn starch magnesium stearate) tablets were given once daily for 6 months along with their standard therapy. The efficacies were assessed by disease activity index (DAI)

frequency difference of the disease flare-up

P<0.05) and erythrocyte sedimentation rate (23.7±11.5 mm/h vs.10.8±3.2 mm/h

关键词

SilymarinUlcerative Colitisrandomized controlled trial

Keywords

SilymarinUlcerative Colitisrandomized controlled trial

references

Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 2007;52:2015–2021.

Hosseini-Tabatabaei A, Abdollahi M. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 2008:7:129–135.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci 2007;52:2920–2925.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad spectrum antibiotic therapy in patients with active Crohn's disease. Clin Ther 2006;28:1983–1988.

Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: a systematic review and meta-analysis of clinical trials. Cent Eur J Med 2009;4:164–170.

Nikfar S, Mirfazaelian H, Abdollahi M. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebocontrolled trials. Curr Pharm Des 2010;16:3684–3698.

Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A metaanalysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci 2009;54:1157–1170.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a metaanalysis. Dig Dis Sci 2009;54:712–721.

Rahimi R, Nikfar S, Abdollahi M. Meta-analysis technique confirms the effectiveness of anti-TNF-α in the management of active ulcerative colitis when administered in combination with corticosteroids. Med Sci Monit 2007;13(7):P13–P18.

Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic metaanalysis of controlled clinical trials. Biomed Pharmacother 2007;61:75–80.

Rahimi R, Nikfar S, Rahimi F, Elahi B, Derakhshani S, Vafaie M, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008;53:2524–2531.

Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci 2007;53:1278–1284.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission. Arch Med Sci 2008;4:185–190.

Nikfar S, Darvish-Damavandi M, Abdollahi M. A review and meta-analysis of the efficacy of antibiotics and probiotics in management of pouchitis. Int J Pharmacol 2010;6:826–835.

Nikfar S, Ehteshami-Afshar S, Rahimi R, Abdollahi M. Systematic review and meta-analysis of the efficacy and tolerability of nicotine preparations in active ulcerative colitis. Clin Ther 2010;32:2304–2315.

Salari P, Abdollahi M. Current opinion in the pharmaceutical management of irritable and inflammatory bowel diseases: role of ATP. Rec Pat Endoc Metab Immun Drug Disc 2009;3:69–75.

Salari-Sharif P, Abdollahi M. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review. Curr Pharm Des 2010;16:3661–3667.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a metaanalysis. Rep Toxicol 2008;25:271–275.

Rahimi R, Mozaffari S, Abdollahi M. On the use of herbal medicines in management of inflammatory bowel diseases: a systematic review of animal and human studies. Dig Dis Sci 2009;54:471–480.

Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol 2010;16:4504–4514.

Esmaily H, Hosseini-Tabatabaei A, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A, et al. On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Cent Eur J Biol 2009;4:204–213.

Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR, Abdollahi M. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol Mech Methods 2011;21:200–208.

Esmaily H, Vaziri-Bami A, Miroliaee AE, Baeeri M, Abdollahi M. The correlation between NF-κB inhibition and disease activity by coadministration of silibinin and ursodeoxycholic acid in experimental colitis. Fundam Clin Pharmacol 2011;25:723–733.

Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G, Taghavi B, et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-β1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci 2006;1091:110–122.

Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani MJ, Mohammadirad A, et al. Study on the correlations among disease activity index and salivary transforming growth factor-β1 and nitric oxide in ulcerative colitis patients. Ann N Y Acad Sci 2007;1095:305–314.

Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004;49:1752–1757.

Hasani-Ranjbar S, Larijani B, Abdollahi M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm Allergy Drug Targets 2009;8:2–10.

Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar N, Ghazanfari G, et al. Benefits of Zataria multiflora boiss in experimental model of mouse inflammatory bowel disease. Evid Base Complement Altern Med 2007;4:43–50.

Ghafari H, Yasa N, Mohammadirad A, Dehghan G, Zamani MJ, Nikfar S, et al. Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity. Hum Exp Toxicol 2006;25:325–332.

Amini-Shirazi N, Hoseini A, Ranjbar A, Mohammadirad A, Khoshakhlagh P, Yasa N, et al. Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by Ziziphora clinopoides (Kahlioti), a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice. Toxicol Mech Methods 2009;19:183–189.

Ghazanfari G, Minaie B, Yasa N, Ashtaral-Nakhai L, Mohammadirad A, Nikfar S, et al. Biochemical and histopathological evidences for beneficial effects of Satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods 2006;16:365–372.

Rastegarpanah M, Omidzohour N, Vahedi H, Malekzadeh R, Hashemian F, et al. Management of human ulcerative colitis by SaturexIM: a randomized controlled trial. Int J Pharmacol 2011;7:415–418.

Abdolghaffari AH, Baghaei A, Moayer F, Esmaily H, Baeeri M, Monsef-Esfahani HR, et al. On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. Hum Exp Toxicol 2010;29:287–295.

Baghaei A, Esmaily H, Abdolghaffari AH, Baeeri M, Gharibdoost F, Abdollahi M. Efficacy of Setarud (IMOD®), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Indian J Biochem Biophys 2010;47:219–226.

Ebrahimi F, Esmaily H, Baeeri M, Mohammadirad A, Fallah S, Abdollahi M. Molecular evidences on the benefit of N-acetylcysteine in experimental colitis. Cent Eur J Biol 2008;3:135–142.

Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, Ashtaral-Nakhai L, Minaie B, Abdollahi M. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease: molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 2007;17:281–288.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Endorsement of CONSORT by Chinese medical journals: A survey of “instruction to authors”

A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism

Effects of Modified Sanhuang Decoction (加味三黄汤) enema on serum tumor necrosis factor-α and colonic mucosa interleukin-1β, interleukin-6 levels in ulcerative colitis rats

Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials

Efficacy of Gastrosis No.1 compound on functional dyspepsia of spleen and stomach deficiency-cold syndrome: A multi-center, double-blind, placebo-controlled clinical trial

Related Author

No data

Related Institution

Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine

First Hospital Affiliated to Tianjin University of Traditional Chinese Medicine

Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine

Department of Epidemiology and Biostatistics, School of Public Health, Peking University

Fujian Provincial Cardiovascular Disease Institute, Provincial Clinical College of Fujian Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰